Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYAMBUTOL vs P.A.S. SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
P. A. S. (p-aminosalicylic acid) sodium is a bacteriostatic agent that competitively inhibits the synthesis of folic acid in Mycobacterium tuberculosis by antagonizing the incorporation of p-aminobenzoic acid (PABA) into dihydrofolate. It is selective for mycobacterial folate synthase.
Treatment of pulmonary tuberculosis in combination with other antituberculosis agents,Treatment of extrapulmonary tuberculosis
Treatment of tuberculosis (TB) in combination with other antituberculosis agents, particularly in multidrug-resistant TB (FDA-approved).,Off-label: Used as a second-line agent in atypical mycobacterial infections and in Crohn's disease (though not FDA-approved for these indications).
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
Oral: 4 g three times daily (total daily dose 12 g); IV: 12 g daily in 2-4 divided doses.
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
1 hour (normal renal function); prolonged to 5-7 hours in anuria or severe renal impairment; clinical context: requires frequent dosing or renal dose adjustment
Partially metabolized in the liver via dealkylation to an aldehyde intermediate, which is further oxidized to a dicarboxylic acid. Approximately 50% of the drug is excreted unchanged in urine.
Primarily metabolized by hepatic acetylation via N-acetyltransferase (NAT); minor pathways include glycine conjugation and renal excretion of unchanged drug.
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
Renal (80% as active drug and metabolites, primarily acetylated form); fecal (minor; <10%)
20-30% bound to albumin.
50-60% (primarily to albumin)
1.6 L/kg; distributes widely into tissues, including erythrocytes and cerebrospinal fluid (with inflamed meninges).
0.5-0.6 L/kg (indicates distribution into total body water, with some tissue binding)
Oral: approximately 80% absorbed.
Oral: approximately 90% (well absorbed from GI tract)
Cr Cl 30-60 m L/min: 15-20 mg/kg daily; Cr Cl 10-29 m L/min: 15 mg/kg every 24-36 hours; Cr Cl <10 m L/min: 15 mg/kg every 48 hours.
Cr Cl <50 m L/min: reduce dose by 50%; Cr Cl <10 m L/min: avoid use or reduce to 25% of normal dose.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
15-25 mg/kg orally once daily (max 1 g/day for children weighing <20 kg, otherwise 2.5 g/day).
Oral: 200-300 mg/kg/day in 3-4 divided doses, maximum 12 g/day.
Consider reduced initial dose based on renal function; monitor for optic neuritis.
Start at lower end of dosing range; monitor renal function and adjust based on Cr Cl; typical initial dose 4 g twice daily.
MYAMBUTOL may cause optic neuritis and decreased visual acuity, which may be dose-related and reversible upon discontinuation. Not recommended for use in children under 13 years of age.
None explicitly stated in current FDA labeling; however, caution is advised in hepatic impairment due to risk of hepatitis.
Optic neuritis (monitor visual acuity and color discrimination); hepatic toxicity; renal impairment (dose adjustment required); interaction with aluminum-containing antacids (decreased absorption).
May cause severe hypersensitivity reactions (e.g., fever, rash, lymphadenopathy).,Hepatic toxicity: risk of hepatitis, especially with prolonged use; monitor liver function.,Renal impairment: dose adjustment required in severe renal disease.,Gastrointestinal intolerance: nausea, vomiting, diarrhea common.,Development of resistance if used as monotherapy.,May induce hemolytic anemia in G6PD deficiency.
Hypersensitivity to ethambutol; optic neuritis (unless benefit outweighs risk); children under 13 years of age (relative contraindication).
Hypersensitivity to p-aminosalicylic acid or any component.,Severe hepatic impairment.,Severe renal failure (unless dose-adjusted).,Contraindicated in patients with active peptic ulcer disease.
No significant food interactions. However, administration with food may reduce gastrointestinal upset. Concurrent use with aluminum-containing antacids may decrease absorption; separate by at least 2 hours.
Take with food, especially acidic foods (e.g., applesauce, yogurt) to improve taste and reduce gastrointestinal irritation. Avoid alkaline foods (e.g., milk, antacids) as they may decrease absorption. Avoid alcohol due to increased risk of hepatotoxicity.
Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant increase in major malformations. However, due to the risk of optic neuritis in the mother, use during pregnancy should be cautious and only if clearly needed.
First trimester: No evidence of teratogenicity in human studies; limited animal data show no adverse effects. Second trimester: No specific risks identified. Third trimester: No known adverse fetal effects; use only if clearly needed.
Ethambutol is excreted into human breast milk in low concentrations; the estimated infant dose is approximately 2-4% of the maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.57. The American Academy of Pediatrics considers ethambutol compatible with breastfeeding. Monitor the infant for signs of optic neuritis or gastrointestinal effects.
Excreted into breast milk in low amounts; M/P ratio not determined. Considered compatible with breastfeeding; monitor infant for diarrhea or rash.
No specific dose adjustments are routinely recommended during pregnancy. However, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may reduce serum concentrations; therapeutic drug monitoring is not standard but may be considered. Adjust dose based on renal function; usual dose is 15-25 mg/kg/day, not to exceed 2.5 g/day.
No pharmacokinetic changes requiring dose adjustment in pregnancy; use standard dosing but monitor for hepatotoxicity, which may be increased.
MYAMBUTOL (ethambutol) is a bacteriostatic agent used primarily in combination therapy for tuberculosis. Monitor for optic neuritis, which can cause decreased visual acuity, color blindness, and visual field defects; baseline and monthly visual acuity and color discrimination tests are mandatory. Dose adjustments required in renal impairment (Cr Cl <30 m L/min). Avoid in children <13 years old due to inability to monitor vision. May cause hyperuricemia; monitor uric acid levels in patients with gout.
Sodium aminosalicylate (PAS sodium) is a second-line antituberculosis agent used in multidrug-resistant TB (MDR-TB). It is bacteriostatic against Mycobacterium tuberculosis by inhibiting folate synthesis. Must be administered with other antitubercular drugs to prevent resistance. Monitor for hepatotoxicity, hypersensitivity reactions (fever, rash, eosinophilia), and gastrointestinal intolerance. Can cause hypothyroidism; monitor thyroid function. Drug interactions: may increase phenytoin levels; avoid concurrent probenecid (increases PAS levels). PAS granules should be sprinkled on soft acidic food to reduce GI upset.
Take exactly as prescribed, usually once daily, with or without food.,Report any changes in vision immediately, such as blurred vision, difficulty seeing colors, or blind spots.,Avoid consuming alcohol; may increase risk of liver toxicity.,Do not stop taking this medication even if you feel better; complete full course to prevent resistance.,This drug may cause numbness or tingling in hands or feet; report these symptoms.,Inform your doctor if you have kidney disease, gout, or eye problems before starting treatment.
Take this medication exactly as prescribed, usually twice daily with food to reduce stomach upset.,Do not skip doses; complete the full course to prevent drug resistance.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe abdominal pain.,Notify your doctor if you develop fever, rash, or unusual tiredness.,You may need regular blood tests to monitor thyroid and liver function.,Avoid alcohol while taking this medication.,Keep all appointments for TB treatment monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYAMBUTOL vs P.A.S. SODIUM, answered by our medical review team.
MYAMBUTOL is a Antitubercular Agent that works by Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.. P.A.S. SODIUM is a Antitubercular Agent that works by P. A. S. (p-aminosalicylic acid) sodium is a bacteriostatic agent that competitively inhibits the synthesis of folic acid in Mycobacterium tuberculosis by antagonizing the incorporation of p-aminobenzoic acid (PABA) into dihydrofolate. It is selective for mycobacterial folate synthase.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYAMBUTOL and P.A.S. SODIUM depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYAMBUTOL is: 15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.. The standard adult dose of P.A.S. SODIUM is: Oral: 4 g three times daily (total daily dose 12 g); IV: 12 g daily in 2-4 divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYAMBUTOL and P.A.S. SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYAMBUTOL is classified as Category C. Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant . P.A.S. SODIUM is classified as Category C. First trimester: No evidence of teratogenicity in human studies; limited animal data show no adverse effects. Second trimester: No specific risks identified. Third trimester: No kn. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.